I. Introduction

Carbinoxamine (CX) (2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N, N-dimethyl-ethanamine) (
) is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It is also used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as docromolyn and nedocromil, carbinoxamine competes with free histamine for binding at HA-receptor sites. Carbinoxamine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than other antihistamines, which probably accounts for the antidyskinetic action of carbinoxamine. Some analytical methods are developed for the estimation of carbinoxamine includes, LC-Tandem mass spectrometry (1, 2), LC (3-5), and gas chromatography (6) and spectrophotometry (7) (8) (9) .
Few combination methods also reported for carbinoxamine with of pseudoephedrine hydrochloride in a pharmaceutical dosage form. Analysis was conducted on a CN column (10 microns), with a mobile phase consisting of acetonitrile-methanol-phosphate buffer (pH 5.3)-water (10). Carina de et al have developed quantitative determination of carbinoxamine acetaminophen and phenylephrine in tablets by high-performance liquid chromatography (11) . Spectrophotometric determination of the antihistamines, carbinoxamine maleate and doxylamine succinate, in an N-cetylpyridinium chloride micellar medium (12) . Hence, in the present investigation, a new LC-MS/MS method has been reported for the estimation of carbinoxamine in human plasma using pargeverine as an internal standard pargeverine ( fig. 2 ).
Experimental
Pure samples of carbinoxamine and pargeverine received as gift sample from RL Fine Chemicals Ltd., Bangalore. Solvents such as acetonitrile, methanol and water used were of HPLC grade. All other chemical like ammonium formate used of AR grade.
Chromatographic and mass spectrometry systems and conditions
The HPLC system was an LC-20 AD series model (Shimadzu), consisted in a binary pump, an in-line degasser, an auto sampler, a column thermostat and an ion trap VL mass spectrometer detector (Bruckner Daltonics GmbH, Germany). The ion transition monitored was: m/z Carbinoxamine (Q 1 Mass: 291.2; Q 3 Mass: 167.1), Internal standard pargeverine (Q 1 Mass: 338.1; Q 3 Mass; 167.0). Chromatographic separation was performed at 45ºC on a BDS HYPERSIL C-8 100 x 4.6mm 5μm column, protected by an in-line filter. The HPLC system was coupled to an MS (ABSICEX API 4000) equipped with an electrospray interface (ESI) operated in the positive ionization mode. Chromatographic and mass spectrometric data acquisitions were performed. The optimization of method parameters are shown in Table 1 . 
Mobile phase
In order to find the suitable mobile phase, which provides a good ionization and a maximum sensibility of the analytical method, a solvent screening was achieved. In all cases the organic solvent used was acetonitrile, in proportion of 53% and to water phase were added salts or organic acids in order to modify the conductibility and the pH. It was compared the ratio signal/noise (S/N) for a standard solution containing carbinoxamine with concentration of 500 ng/mL, both in negative (MS2), positive (MS3) ionization ( Fig. 3 ) and internal standard (Fig. 4) . The suitable mobile phase proved to be a mixture of acetonitrile: buffer (25mm ammonium formate solution) (80:20) using ESI positive ionization. The pump delivered it at 1 mL/min.
Sample preparation
Plasma samples were prepared as follows in order to be chromatographically analyzed: in an Eppendorf tube (max 1.5 mL), 100µl spiked plasma and 50µl Internal standard (pargeverine) were added. To this 500µl of acetonitrile was added. The tube was vortex-mixed for 10min (Vortex Genie 2, Scientific Industries) and centrifuged for 5 min under 4ºC at 4500 rpm (Thermo Fischer scientific). The supernatant of 5μl was transferred to an auto sampler vial and was injected into the HPLC system.
Preparation of standard blank and zero standard samples
The standard blank samples were prepared by transferring 0.5 mL screened blank plasma into prelabeled vials. The zero standard was prepared by adding 20µL of internal standard solution (pargeverine) (1.0 µg/mL) into 0.5 mL screened blank plasma into a pre-labeled vial and vortex for 15 seconds. 
Preparation of calibration curve solutions and samples
The calibration curve standards spiking solutions were prepared by adding 20 µL of drug stock solution (1.0 mg/mL) with diluents (Methanol: Water, 50:50%v/v) in different vials and add 20 µL internal standard pargeverine solution (1.0 µg/mL) and vortex for 15 seconds. Prepare the calibration curve standards by spiking the respective calibration curve standards spiking solutions in screened blank plasma in different vials to obtain final concentration of 5, 10, 30, 50, 100, 500, 1000, 3000 and 5000 ng/mL of carbinoxamine.
Preparation of quality control solutions and samples
The quality control spiking solutions were prepared by adding 20 µL of drug stock solution (1.0 mg/mL) with diluents (Methanol: Water, 50:50%v/v) in different vials and add 20 µL internal standard solution (1.0 µg/mL) and vortex for 15 seconds. Prepare the quality control samples by spiking the respective quality control spiking solutions in screened blank plasma in different vials to obtain lower limit of quantification quality control (LLOQ QC), lower quality control (LQC), middle quality control-2 (MQC2), middle quality control-1 (MQC1), higher quality control (HQC) and upper limit of quantification quality control (ULOQ QC) samples of concentrations of 5, 30, 125, 500, 1250 and 5000 ng/mL of carbinoxamine. The LLOQ QC and ULLOQ QC solution were prepared only for method validation and screening of blank plasma samples.
Preparation of working solutions for stability testing
The working spiking solutions were prepared for long-term solution stability and short-term solution stability by adding drug stock solution (1.0 mg/mL) with diluents (methanol: water, 50:50% v/v) in different vials and vortex for 15 seconds.
II. Method validation
The method performance was evaluated for selectivity/selectivity, accuracy, precision, linearity, and limit of detection and limit of quantification etc. [13, 14] .
The specificity/selectivity of method was evaluated by analyzing 6 replicates of blank plasma samples and 6 spiked plasma samples at LLOQ (Lower Limit of Quantification = 0.5 ng/mL). The chromatographic systems used for analysis should pass the system suitability limits before sample analysis. Set up the chromatographic system, Inject blank preparation (single injection) and standard preparation (six replicates) and record the chromatograms to evaluate the system suitability parameters like resolution (NLT 2.0), tailing factor (NMT 1.5), theoretical plate count (NLT 3000) and % RSD for peak area of six replicate injections of LMS standard (%RSD NMT 2.0). The recovery was evaluated by comparing response of extracted and unextracted samples. Extracted samples include six replicates of extracted LQC, MQC and HQC samples. Unextracted samples included the aqueous solutions equivalent to extracted samples. The average recovery for carbinoxamine in plasma was ranged from 78.32 to 96.84 % for the low, medium and high quality control samples with an average of 88.31% represented in table 2. The LOQ is defined as the concentration level of carbinoxamine at five times its half-life and providing an S/N ratio of 8.7. The LOQ of carbinoxamine in human plasma was 0.5ng/mL. The LOD of carbinoxamine was found to be 0.178 ng/ml. Accuracy and precision was evaluated by analysing 3 batches. Each batch consists of six replicates of LQC, MQC and HQC. Precision was evaluated for both interday and intraday batches. The interday and intraday precision and accuracy of the method for each carbinoxamine concentration levels (20, 40 and 200 ng/mL).
III. Results and discussion
The method validation of bioanalysis was performed as stated in US-FDA guideline. Specificity, selectivity, system suitability, % recovery, linearity, limit of detection, limit of quantitation, accuracy and precision were analyzed.
The specificity/selectivity of the method was investigated by analyzing six blank human plasma extract (n=6) and extract of spiked drug (Table 2) . No significant interference in the blank plasma traces was seen from endogenous substances in drug free human plasma at the retention time of the analyte. Under the chromatographic conditions described, carbinoxamine and the internal standard were eluted with nearly the same retention time. System suitability was studied under each validation parameter by injecting six replicates of the standard solution. The system suitability parameters are given in Table 3 .
The lower limit of detection (LOD), was shown to be 0.05 ng/mL. The lower limit of quantitation (LLOQ) found to be 0.2 ng/mL in human plasma. The mean response for analyte peak at the assay sensitivity limit (0.2 ng/mL) was about 5 fold greater than the mean response for peak in six blank human plasma samples at the retention time of the analyte. The between-batch precision at the LLOQ was 3.475% and between-batch accuracy was 99.18% (Table 4) . Prepared six sets of recovery comparison samples by spiking 50 μL of spiking dilution of quality control samples (LQC, MQC, MQC1 and HQC) carbinoxamine of in 950 μL eluent of extracted blank. The mean overall recovery of carbinoxamine was 74.61% with a precision of 4.67% & mean recovery of internal standard (pargeverine) was 77.49%. For LLOQQC, the intra-day precision ranged from 4.39% to 7.39% and the intra-day accuracy ranged from 99.16% to 105.55% for carbinoxamine (Table 5) . For LLOQ QC, the inter-day precision was 6.45% and the inter-day accuracy was 100.29% for carbinoxamine ( Table 6 ). The results showed that for within run and between run experiments the precision and accuracy for the analyte were within the acceptance criteria. The bioanalytical methodology described in this report was specific, sensitive, accurate and precise enough to be successfully applied to pharmacokinetics study. The method employed sample preparation by solid phase micro extraction (SPME) appeared to be adequate recovery including less time consuming, and was followed by gradient HPLC coupled with tandem mass spectrometric detection (LC-MS/MS).
The LC-MS/MS method could be used to determination of carbinoxamine in human plasma, in the concentration range 0.2-80 ng/mL. There were no interferences from endogenous plasma component or other sources. The need for plasma volume less than 250 mL for each sample made it possible to decrease volume of sample preparation per time. The method was successfully validated and proved appropriate for the analysis of carbinoxamine in human plasma and can be applied for pharmacokinetics studies. The analytical method presented here has proved to be useful for investigation of the characteristics of carbinoxamine in human plasma in pharmacokinetic and pharmacogenetic studies.
